Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2013. The report details a specific share repurchase transaction executed on June 18, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 447,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,689.50 pence per share; lowest price paid was 1,670.50 pence per share.
- Treasury Holdings (Settled): 510,741,512 shares (9.41% of total issued share capital).
- Treasury Holdings (Including Unsettled): 512,049,512 shares (10.41% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,919,237,661 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 447,000 shares on June 18, 2013. Consequently, the percentage of shares held in Treasury increased to 10.41% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (510,741,512 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,919,237,661 shares in issue) for disclosure threshold assessments under FCA rules.
- Review the price paid per share (1,670.50 to 1,689.50 pence) relative to the market price on June 18, 2013.
- Check the status of the 1,308,000 shares purchased but not yet settled to confirm final Treasury holdings.